Xenetic Biosciences (NASDAQ:XBIO) Posts Earnings Results, Misses Estimates By $0.48 EPS

Xenetic Biosciences (NASDAQ:XBIO) posted its quarterly earnings data on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48), Zacks reports. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%.

Xenetic Biosciences Stock Performance

Shares of Xenetic Biosciences stock traded down $0.21 on Tuesday, hitting $3.46. 13,751 shares of the company traded hands, compared to its average volume of 12,669. The stock has a market capitalization of $5.34 million, a P/E ratio of -1.30 and a beta of 2.17. Xenetic Biosciences has a 52 week low of $2.78 and a 52 week high of $5.20. The business has a 50-day simple moving average of $4.03 and a 200 day simple moving average of $4.01.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.